Genetic polymorphisms and early-onset prostate cancer: A real potential to personalize prostate cancer screening?

Future Oncology

Volumn 5, Issue 7, 2009, Pages 923-926

  Hughes, Lucinda ^a   Giri, Veda N ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; BRCA2 PROTEIN; PROSTATE SPECIFIC ANTIGEN;

ALLELE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CHROMOSOME 8Q; CLINICAL TRIAL; EARLY DIAGNOSIS; EDITORIAL; FAMILIAL CANCER; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK ASSESSMENT; GENETICS; MALE; MASS SCREENING; PATIENT CARE; PROSTATE TUMOR;

EARLY DETECTION OF CANCER; HUMANS; MALE; MASS SCREENING; PATIENT-CENTERED CARE; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS;

EID: 73349097262     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.75     Document Type: Editorial

References (24)

1. Cancer Facts and Figures 2009. American Cancer Society, Atlanta, GA, USA (2009).
2. Lin DW, Porter M, Montgomery B: Treatment and survival outcomes in young men diagnosed with prostate cancer: a population-based cohort study. Cancer 115(13), 2863-2871 (2009).
3. Catalona WJ, Antenor JA, Roehl KA, Moul JW: Screening for prostate cancer in high risk populations. J. Urol. 168(5), 1980-1983 (2002).
4. Giri VN, Beebe-Dimmer J, Buyyounouski M et al.: Prostate cancer risk assessment program: a 10-year update of cancer detection. J. Urol. 178(5), 1920-1924 (2007).
5. Andriole GL, Grubb RL 3rd, Buys SS et al.: Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360(13), 1310-1319 (2009).
6. Schroder FH, Hugosson J, Roobol MJ et al.: Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360(13), 1320-1132 (2009).
7. Levin AM, Zuhlke KA, Ray AM, Cooney KA, Douglas JA: Sequence variation in a-methylacyl-CoA racemase and risk of early-onset and familial prostate cancer. Prostate 67(14), 1507-1513 (2007).
8. Levin AM, Machiela MJ, Zuhlke KA et al.: Chromosome 17q12 variants contribute to risk of early-onset prostate cancer. Cancer Res. 68(16), 6492-6495 (2008).
9. Ross PL, Cheng I, Liu X et al.: Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer. BMC Cancer 9, 69 (2009).
10. Cancer Statistics, Surveillance Epidemiology and End Results. National Cancer Institute, MD, USA (2009).
11. Amundadottir LT, Sulem P, Gudmondsson J et al.: A common variant associated with prostate cancer in European and African populations. Nat. Genet. 38(6), 652-658 (2006).
12. Gudmundsson J, Sulem P, Manolescu A et al.: Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat. Genet. 39(5), 631-637 (2007).
13. Yeager M, Orr N, Hayes RB et al.: Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet. 39(5), 645-649 (2007).
14. Wang L, McDonnell SK, Slusser JP et al.: Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res. 67(7), 2944-2950 (2007).
15. Beebe-Dimmer JL, Levin AM, Ray AM, et al.: Chromosome 8q24 markers: risk of early-onset and familial prostate cancer. Int. J. Cancer 122(12), 2876-2879 (2008).
16. Gudmundsson J, Sulem P, Steinthorsdottir V et al.: Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against Type 2 diabetes. Nat. Genet. 39(8), 977-983 (2007).
17. Eeles RA, Kote-Jarai Z, Giles GG et al.: Multiple newly identified loci associated with prostate cancer susceptibility. Nat. Genet. 40(3), 316-321 (2008).
18. Camp NJ, Farnham JM, Wong J et al.: Replication of the 10q11 and Xp11 prostate cancer risk variants: results from a Utah pedigree-based study. Cancer Epidemiol. Biomarkers Prev. 18(4), 1290-1294 (2009).
19. Douglas JA, Levin AM, Zuhlke KA et al.: Common variation in the BRCA1 gene and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 16(7), 1510-1516 (2007).
20. Douglas JA, Zuhlke KA, Beebe-Dimmer J et al.: Identifying susceptibility genes for prostate cancer - a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-β. Cancer Epidemiol. Biomarkers Prev. 14(8), 2035-2039 (2005).
21. Edwards SM, Kote-Jarai Z, Meitz J et al.: Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am. J. Hum. Genet. 72(1), 1-12 (2003).
22. Nam RK, Zhang WW, Trachtenberg J et al.: Utility of incorporating genetic variants for the early detection of prostate cancer. Clin. Cancer Res. 15(5), 1787-1793 (2009).
23. Zheng SL, Sun J, Wiklund F et al.: Cumulative association of five genetic variants with prostate cancer. N. Engl. J. Med. 358(9), 910-919 (2008).
24. Salinas CA, Koopmeiners JS, Kwon EM et al.: Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate 69(4), 363-372 (2009).